Viz.ai and Vastrax join forces to accelerate neurovascular clinical trial enrolment

73

Viz.ai has announced a strategic partnership with full-service, vascular clinical research organisation (CRO) Vastrax. Together, the two companies intend to accelerate clinical trial enrolment for research on novel neurovascular therapies.

“Continued development of new technologies in neurointervention is the key to bringing better treatment options to patients, and proving the safety and benefit of these technologies in the right patient population is fundamental to success,” said Adnan Siddiqui (State University of New York at Buffalo, Buffalo, USA). “Viz.ai and Vastrax will enable accelerated and improved clinical trial enrolment and therefore quicker route to market for many new neurovascular devices.”

Viz’s RECRUIT software, which a company press release states has demonstrated 3×1 acceleration in clinical trial enrolment, will become Vastrax’s artificial intelligence (AI)-powered clinical trial recruitment platform for its neurovascular trials. Viz RECRUIT identifies trial-eligible patients by scanning patient images in real-time, enabling around-the-clock, automatic identification of potential study subjects with notifications sent to research teams.

Viz.ai’s cloud-based technology broadens the recruitment funnel in both size and diversity, and streamlines trial enrolment workflow, the release adds.

“We are pleased to partner with Vastrax to advance important clinical research,” said Jayme Strauss, chief clinical officer at Viz.ai. “Viz’s AI-powered recruitment software, combined with Vastrax’s deep expertise in neurovascular and vascular clinical trials, will help increase access and diversity in research to get new therapies to patients faster.”

“We believe that, together, with the Viz RECRUIT platform, Vastrax’s clients will more quickly enrol a broader patient population in their clinical trials, enabling accelerated market access and potentially broader indications. This will enable a big leap in endovascular trial execution, with the view to more patients safely accessing new technologies faster,” added Ryan Bouchard, president at Vastrax.


LEAVE A REPLY

Please enter your comment!
Please enter your name here